REVOLUTION MEDICINES INC

Revolution Medicines CEO sells option‑acquired shares amid a brokerage price‑target upgrade—insider liquidity, strong revenue growth, and strategic reimbursement plans reveal a biotech firm poised for long‑term growth.

Revolution Medicines CFO’s recent insider trades show routine portfolio moves, with a net 4% gain—no strategic shift, just standard 10(b)(5)(1) activity.

Revolution Medicines CFO’s June 24 trades reveal insider confidence and regulatory strategy, offering investors insight into the company’s governance and future outlook.

Revolution Medicines files a routine insider sale under Rule 144, but its oncology pipeline and FDA plans for RMX‑101 remain on track, offering a new lung‑cancer option.

Revolution Medicines’ 10‑b5‑1 sales show prudent tax‑liquidity handling while maintaining a strong pipeline, positive cash flow and a cost‑effective tech strategy that boosts payer appeal and patient access in oncology.

Revolution Medicines COO Margaret Horn’s insider trades reveal how executive equity activity under a 10(b)(5) plan can boost investor confidence and align management with shareholder interests.

Revolution Medicines’ Rule 144 filings show routine RSU sales and a $14 m officer sale that’s under 0.5% of shares—minimal impact on value or strategy.

Phase 3 data show daraxonrasib extends survival and quality‑of‑life for metastatic pancreatic cancer, offering a new oral RAS inhibitor with fewer side‑effects than chemo.

Revolution Medicines’ inclusion in GraniteShares’ leveraged ETF signals growing investor appetite for high‑growth biotech. Explore how RM’s clinical milestones and regulatory designations could shape future stock volatility and patient outcomes.

Revolution Medicines launches an expanded access program for daraxonrasib, a KRASG12D‑targeted agent boosting survival in pancreatic cancer patients with limited options.